The effects of interleukin-1, granulocyte macrophage colony-stimulating factor, and tumor necrosis factor-α on cultured human langerhans cells and cortical thymocytes by Kolenik, Steven Andrew, III
Yale University
EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library School of Medicine
1990
The effects of interleukin-1, granulocyte
macrophage colony-stimulating factor, and tumor
necrosis factor-α on cultured human langerhans
cells and cortical thymocytes
Steven Andrew Kolenik III
Yale University
Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl
Part of the Medicine and Health Sciences Commons
This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital
Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.
Recommended Citation
Kolenik, Steven Andrew III, "The effects of interleukin-1, granulocyte macrophage colony-stimulating factor, and tumor necrosis





Permission for photocoping or microfilming of 11 ' 
(Title of thesis) Cglfe Cor^icAl- 
for the purpose of individual scholarly consultation or reference 
is hereby granted by the author. This permission is not to be 
interpreted as affecting publication of this work or otherwise 
placing it in the public domain, and the author reserves all rights 
of ownership guaranteed under common law protection of unpublished 
manuscripts. 
Digitized by the Internet Archive 
in 2017 with funding from 




The Effects of lnterleukin-1, Granulocyte Macrophage Colony- 
Stimulating Factor, and Tumor Necrosis Factor-a on Cultured 
Human Langerhans Cells and Cortical Thymocytes 
A Thesis Submitted to the Yale University 
School of Medicine in Partial Fulfillment 
of the Requirements for the Degree of 
Doctor of Medicine 
by 
Steven Andrew Kolenik III 
1990 
M e J . L\ b . 
T II 5 
+ Y I 2. 
5 g 2-5 
Acknowledgments 
I wish to thank my advisors 
B Jack Longley MD 
and 
Richard L Edelson MD 
for their help and guidance 
in producing this thesis 
and 
Tie Gang Ding MD 




Langerhans cells (LC) are bone marrow derived residents of 
the epidermis which express the CDIa surface antigen and 
undergo a variety of phenotypic and functional changes in vitro. 
To determine the effects of the epidermally associated cytokines 
granulocyte macrophage colony-stimulating factor (GM-CSF), 
Tumor Necrosis Factor-a (TNF-a), and lnterleukin-1 (IL-1) on LC 
phenotype in vitro, epidermal cells were cultured in the presence 
of these cytokines and the percentage of cells expressing CDIa 
was determined by flow cytometry. By the fifth day, the 
percentage of cells expressing CDIa in TNF-a and control cultures 
was about half of the starting value, while in IL-1 and GM-CSF 
cultures CDIa expression was respectively higher and lower than 
control. To determine if these effects on CDIa expression are 
generalizable, expression of CDIa by human cortical thymocytes 
was also studied. GM-CSF decreased and IL-1 increased 
thymocyte CDIa expression. In additon, these two cytokines had 
opposite effects on class I major histocompatibility complex 
(MHC) protein expression, suggesting that these two antigens are 
reciprocally regulated. To correlate these phenotypic changes 
with function, LC precultured with cytokines were tested for 
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their ability to stimulate allogeneic T-cell proliferation. GM-CSF 
treated cultures caused 2 to 3 times more T-cell proliferation 
than control cultures. Addition of antibodies reactive with class 
I and class II MHC molecules blocked T-cell proliferation while 
antibodies to CDIa did not. We conclude that GM-CSF, a cytokine 
that is produced by keratinocytes and thymic nonlymphoid cells in 
vitro, can decrease CDIa expression by thymocytes and LC, while 
increasing class I MHC expression by thymocytes. Furthermore, 
GM-CSF enhances the ability of human LC to stimulate allogeneic 
reactions in vitro. This ability can be blocked by antibodies to 
both class I and class II MHC molecules. 
Introduction 
Langerhans cells (LC) are a minor population of epidermal 
cells that have been the subject of a large body of research since 
their discovery by Paul Langerhans in 1868. Langerhans believed 
that the dendritic cells he had discovered with gold chloride 
staining were intraepithelial receptors for extracutaneous 
signals to the nervous system [1], and such a theory prevailed for 
a century. In 1968, however, Breathnach et al proved that murine 
Langerhans cells do not originate in the neural crest, by 
demonstrating that murine skin deprived of its neural crest 
components still contained LC [2]. Further experiments carried 
out by Frelinger et al using murine radiation chimeras 
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reconstituted with allogeneic bone marrow demonstrated that LC 
originate in bone marrow [3]. These findings were confirmed in 
similar experiments by Katz et al in the same year [4]. 
Subsequent studies in humans after male to female bone marrow 
transplantation, have established the bone marrow origin of 
human LC by demonstrating the presence of exclusively Y 
chromosome-positive LC (donor LC) in the skin biopsies of female 
bone marrow transplant recipients [5,6]. 
During the 1970's a large body of evidence accumulated that 
phenotypically linked LC to cells of the macrophage/monocyte 
lineage. Both types of cells express Fc and C3 receptors [7], HLA- 
DR (Class il major histocompatibility complex) molecules [8,9], 
membrane ATPase activity [11], and have the ability to migrate 
[10]. Based on these findings, as well as ultrastructural evidence 
[12,13], Katz et al has suggested that monocytes are the most 
likely precursors of epidermal LC [4], however formal proof of a 
specific LC precursor is lacking. 
In contrast to the similarities between LC and 
macrophage/monocytes, several phenotypic and structural 
features distinguish LC from all other cells studied to date. Most 
striking of these features is a cytoplasmic structure known as 
the Birbeck granule. In 1961, Birbeck published the first electron 
micrographs of epidermal LC in which a unique membrane bound 
granule was observed. Birbeck described this cytoplasmic 
granule as a linear structure with rounded ends and a striated 
line running down the center [14]. This is the typical "tennis 
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racket" shape that is usually associated with Birbeck granules. 
Recent evidence has suggested that these granules are involved in 
receptor mediated endocytosis along with lysosomes, coated pits, 
and coated vesicles [15,16,36], and they remain the gold standard 
for the identification of epidermal LC. 
Epidermal LC are also unique in their surface antigen profile. 
As mentioned above, they express class II MHC protiens, however, 
there is controversy as to whether they express very low levels 
of class I MHC molecules [17,71], or are totally deficient in class 
I MHC protein expression [18,19]. This relative lack of class I 
MHC protein expression by LC is quite unusual and is shared only 
with certain subsets of cortical thymocytes [37]. In addition, LC 
express the CDIa surface antigen which is a glycoprotein with a 
relative mass of 49,000 [20,21]. CDIa has also been called "T6" 
because it is recognized by the OKT6 monoclonal antibody [21], 
and is biochemically identical to Human Thymocyte Antigen 1 
(HTA-1) [22,23] which is expressed by cortical thymocytes 
[24,25]. In the further biochemical characterization of the CDIa 
molecule several similarities to class I MHC protiens have been 
noted. CDIa and class i MHC molecules share serologically 
defined epitopes [26] and have biochemically similar structures 
including three extracellular domains named a-1, a-2, and a-3 
[26-35]. CDIa and class I MHC protiens both associate with (3-2 
microglobulin through their a-3 domain [29-31], and both have 
been reported to associate with the CD8 thymocyte surface 
molecule [32,33]. In addition, the predicted secondary structure 
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of the a-1 and a-2 domains of CDIa is very similar to the antigen 
binding pocket of HLA-A2, which is a well characterized class I 
MHC molecule [27,28]. As a result of these similarities, it has 
been argued that CDIa represents a novel type of class I MHC 
molecule [30,31], and as such may be involved in the presentation 
of antigen to T-cells [26-33]. While presentation of antigen by 
CDIa has not been proven, CDIa does appear to be part of a 
receptor site since it is internalized via coated pits, coated 
vesicles, and endosomes in ways characteristic of receptor 
mediated endocytosis [36]. It is also intriguing that LC and 
cortical thymocytes are the only cells expressing CDIa and are 
the only nucleated somatic cells deficient in class I MHC protein 
expression [37,38]. The structural similarities, together with the 
reciprocal anatomic distribution of CDIa and class I MHC 
molecules, suggests that these molecules may perform either 
similar, or mutually exclusive functions. 
While recent work has focused on the precise role of immune 
function associated molecules such as CDIa expressed by LC, the 
function of LC themselves has been studied and debated since 
their discovery. As mentioned above, Langerhans himself initially 
believed that these cells were part of the peripheral nervous 
system [1], however, in 1882 he published a short correction of 
his original paper of 1868 stating "I am now convinced . . . that 
my cells are in no way essential for nerve endings" [39]. He 
appearently based this correction on the histological work of 
Mojsisovics and Merkel [39]. Langerhans' retraction went largely 
7 

unnoticed, and little progress was made toward the understanding 
of LC function for more than a century. In 1973, however, 
Silberberg described the apposition of LC and mononuclear 
lymphocyte-like cells in man, within 4-6 hours of the topical 
application of mercury bichloride, which is known to induce 
contact hypersensitivity [10]. Furthermore, this apposition was 
identified only in subjects with allergic reactions to mercury 
bichloride, and not in subjects with primary irritant reactions, or 
no reaction to mercury bichloride [10,40,41]. In addition, it has 
been shown that contact sensitivity to a specific allergen can be 
passively transferred by lymph node cell suspensions from 
sensitive to naive animals, and after dermal challenge with the 
allergen, allergen bearing LC are found in lymph nodes of the 
formerly naive animals [42,46]. Subsequent studies have proven 
that LC can pick up antigen in the skin and carry it by way of 
dermal lymphatics, to draining lymph nodes [42-45]. These 
findings firmly established an immunological role for LC and 
strongly suggested that they may be involved in the presentation 
of antigen to T-cells in lymph nodes. In vivo proof of the antigen 
presenting capacity of LC has accumulated from two other types 
of observations as well. In the first, it has been noted that 
cutaneous surfaces devoid of LC do not support the development 
of contact hypersensitivity after application of allergen [59-61]. 
In the second, LC deficient allografts such as tape-stripped skin 
and cornea, have been shown to lack the ability to induce 
alloimmune reactions [62-65]. More recently Cruz et al have 
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reported that intravenously infused murine LC migrate 
preferentially to skin where they can participate in the induction 
of contact hypersensitivity [66]. In summary it is known that LC 
originate in bone marrow, migrate to the epidermis where they 
pick up antigen, and then transport antigen to draining lymph 
nodes where they stimulate antigen specific immune responses. 
The in vivo findings discussed above have been supported by 
many studies of LC in vitro. While epidermal LC do not survive in 
culture for more than 6 to 9 days [69,70], recent interest has 
focused on marked changes in their observed phenotype and 
function in vitro. As mentioned above, freshly isolated LC 
express class II MHC [8,9] and CDIa surface antigens [21] and 
little or no class I MHC protein [17-19]. However, when 
maintained in culture for 2 to 3 days, LC show increased 
expression of class I MHC and class II MHC antigens, while losing 
CDIa positivity [71,72]. These phenotypic changes have been 
related to changing functional activities of LC such as processing 
antigen in the skin, and then presenting it in draining lymph nodes 
[75]. Studies of human LC have shown that they can substitute for 
macrophages in presenting a variety of antigens such as 
tuberculin protein, herpes simplex virus proteins, trichophytin, 
and nickel sulfate to autologous T-cells from sensitized donors 
[47-50]. In addition, studies in both animals and humans have 
shown that LC enriched epidermal cell suspensions, but not LC 
depleted suspensions, induce a strong proliferative response from 
resting allogeneic T-cells in mixed epidermal-lymphocyte 
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reactions (MELR's) [50,51]. This stimulation has been shown to 
occur in an MHC class II restricted fashion [52-53]. Since it is 
the CD4 glycoprotien which recognizes antigen complexed to MHC 
class II molecules [54-58], this stimulation probably involves 
CD4+ cells, such as T-helper lymphocytes. Functional studies 
comparing the abilities of freshly isolated and cultured murine LC 
have shown that freshly isolated LC actively present protein 
antigens such as myoglobin to specifically primed T-cells, but 
are relatively poor stimulators of allogeneic T-cells in MELR's 
[73]. However, after culture for two to three days, murine LC 
present protein antigen only very weakly, while their ability to 
stimulate allogeneic T-cells increases roughly ten fold [73-75]. 
Similar studies by Teunissen and Romani have shown that the 
ability of human LC to stimulate allogeneic reactions increases 
two to ten fold after 3-5 days of culture [76,71]. Teunissen has 
suggested that this increased ability to stimulate allogeneic T- 
cells may be due to increased MHC class II protein expression on 
cultured LC [76], however, the relationship between the 
phenotypic and functional changes seen in cultured LC has not 
been clearly defined. All of the above observations from in vitro 
and in vivo studies have led to the conclusion that LC are the 
primary antigen presenting cells of the skin [67], and have 
implicated LC as the most peripheral component of a unique 
collection of cells and lymphoid organs called skin-associated 
lymphoid tissues (SALT) that function as a group to perform the 
specialized immune requirements of the skin [68]. 
• 
Most recently, reports from work in murine systems have 
shown that epidermally associated cytokines such as Interleukin- 
I (IL-1), Granulocyte Macrophage-Colony Stimulating Factor (GM- 
CSF), and Tumor Necrosis Factor-a (TNF-a), may influence LC 
phenotype and function in vitro [69,77-79]. Specifically, Witmer- 
Pack and collegues have shown that the addition of GM-CSF to 
murine LC cultures has three effects over a 2-3 day culture 
period: cell viability is increased, LC become larger and more 
dendritic, and their stimulatory ability for allogeneic T-cells 
increases 10 to 20 fold [77]. Similar work by Heufler et al using 
several measures of stimulatory ability has comfirmed that it is 
the direct effect of GM-CSF, and not simply improved viability 
which leads to this enhancement in function [69]. In addition, 
they showed that a combination of IL-1 and GM-CSF added to 
murine LC cultures leads to a 2 fold further increase in 
stimulatory capacity compared to LC cultured with GM-CSF alone 
[69]. TNF-a has been shown to enhance murine LC viability in 
vitro, however, TNF-a treated LC remain relatively poor 
stimulators of allogeneic T-cells [78]. In phenotypic studies 
Belsito et al have recently reported an enhancement of MHC class 
II antigen expression by murine LC cultured in the presence of 
either IL-1, GM-CSF or TNF-a [79]. Evidence of the effects of 
these cytokines on human epidermal cells is scarce. However, 
Walsh et al report that IL-1 can induce CDIa expression on human 
gingival epithelial cells [80]. All of these in vitro findings may 
have important implications for the regulation of LC phenotype 

and function in vivo since it is known that cultured human 
keratinocytes produce IL-1 [79], and GM-CSF [82]. It has also been 
shown recently that TNF-a message is detectable in human 
epidermal mRNA preparations [Longley et al in preparation]. When 
injected intraveneously in mice, TNF-a targets specifically to the 
skin [83], indicating the presence of receptors for TNF-a, and 
suggesting that this cytokine plays a role in the biology of the 
skin. To determine how these cytokines affect the phenotypic 
characteristics of human LC in vitro, we cultured purified LC 
from normal human skin with IL-1, GM-CSF, and TNF-a, and 
compared CDIa expression with untreated cultures. In a similar 
set of experiments we cultured human cortical thymocytes, which 
also express CDIa, with the same cytokines and measured both 
CDIa and class I MHC expression. To assess the functional 
effects of these cytokines, we compared the ability of treated 
and untreated human LC to stimulate proliferation of allogeneic 
T-cells, and attempted to block this proliferation with a variety 
of monoclonal antibodies. T-cell stimulation was measured 
through standard techniques of the MELR. 
Materials and Methods 
Isolation of Langerhans Cells 
Normal human skin was obtained from elective plastic surgery 
procedures and trimmed to the level of the papillary dermis. Skin 

was then incubated in Tyrodes solution with 10 mg/ml Dispase 
(Boerhinger Mannheim, W. Germany) overnight at 4°C and then at 
37°C for 20 minutes. Dispase is a neutral protease which 
selectively digests fibronectin and type IV collagen [87] thus 
allowing sheets of epidermis to be easily separated from the 
dermis and assuring that only epidermal cells were studied. 
Epidermal sheets were then incubated at 37°C for 15 minutes in 
0.125% Trypsin (Gibco Labs Inc., Grand Island, New York), vortexed 
at low speed for 1-2 minutes and filtered through three layers of 
sterile gauze. The resulting epidermal cell suspension was then 
layered over Histopaque-1077 (Sigma Diagnostics, St. Louis, Mo.) 
at 4°C and centrifuged at 300 g's for 20 minutes. Cells remaining 
at the interface were collected, viability assessed by trypan blue 
exclusion, and the percentage of cells expressing CDIa measured 
by flow cytometry after staining with OKT6 monoclonal antibody 
(from ATCC hybridoma # CRL 8020), and FITC conjugated goat 
anti-mouse secondary antibody (Becton Dickinson, Mountain View, 
CA). This technique reliably yielded 97-100% living cells and a 
maximum of 30% CDIa positivity. In some LC experiments, a 
further enrichment for CDIa positive cells was carried out by 
staining interface cells with an anti-class I MHC monoclonal 
antibody (anti-HLA-A,B,C from the W6/32 hybridoma ATCC # 
HB95) and counterstaining with an iron conjugated goat anti¬ 
mouse secondary antibody (Advanced Magnetics Inc., Cambridge, 
MA.). These cells were then precipitated to a magnetic plate 
(Advanced Magnetics Inc.) and nonmagnetic cells were washed 
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from the plate. This procedure increased the percentage of GDI a 
positive cells from a maximum of 30% with Histopaque 
enrichment alone, to a maximun of 50%. 
Langerhans Cell Cultures 
Cells were then plated out at 1X10® cells/ml in 24 well flat 
bottomed plates (Corning Glass Works, Corning, NY) in RPMI 1640 
(Gibco Labs Inc.), 10% defined fetal bovine serum (HyClone Labs 
Inc., Logan, UT), 1% Penicillin G/Streptomycin/Amphotericin B 
(Gibco Labs Inc.) and lOng/ml of recombinant human IL-1, GM-CSF 
(gift of Dr. Steven Gillis, Immunex Corp., Seattle, WA.), or TNF-a 
(courtesy of Dr. Thomas Kupper, Yale School of Medicine, Dept of 
Dermatology) versus control. Viability and GDI a positivity were 
assessed on day .0, 2, 3, and 5 of culture by flow cytometry. 
Thymocyte Isolation 
Thymus glands were obtained from newborn infants during the 
course of corrective cardiac surgery, minced, suspended in RPMI 
1640 (Gibco Labs Inc.), and filtered through sterile gauze. The 
resulting cells were purified on a Histopaque-1077 (Sigma 
Diagnostics) gradient as for LC, and then cultured at 1X107 
cells/ml with conditions and cytokines as for LC. In a series of 
depletion experiments, GDI a, or class I MHC positive cells were 
depleted from thymus gland cell suspensions before culture using 
the appropriate monoclonal antibody, and the magnetic technique 
detailed above. In all cultures, the percentage of cells expressing 
, 
CDIa and class I MHC was determined on day 0 and 8 by flow 
cytometry. 
Preparation of T-cells 
Resting allogeneic T-cells for mixed cultures were prepared 
as follows: Peripheral mononuclear cells (PMN) were obtained 
from the blood of healthy volunteers through Histopaque density 
gradient centrifugation as above. PMN were then suspended in 
RPMI 1640 (Gibco Labs Inc.), 10% defined fetal bovine serum 
(HyClone Labs Inc.), 1% Penicillin G/Streptomycin/Amphotericin B 
(Gibco Labs Inc.) at 1X107 cells/ml and monocytes allowed to 
adhere to a plastic culture flask (Corning Glass Works) for 3-12 
hr.s. Medium containing nonadherent cells (lymphocytes) was 
then decanted and the cells stained with an anti-class II MHC 
protein antibody which reacts with HLA-DR, DP, (and possibly DQ) 
framework determinant produced by the IVA12 hybridoma (ATCC 
#HB 145). Resting T-cells were then negatively selected with 
the magnetic procedure described above. This procedure reliably 
yielded a cell suspension of 94-97% T-cells as assessed by 
expression of T-cell receptor associated antigen (CD3) by flow 
cytometry. 
Mixed Epidermal Cell-Lymphocyte Cultures 
Epidermal cells were prepared and cultured as above except 
that they were plated out in triplicate over a range of 0-3000 LC, 
in 200 microliters per well, in 96 well round bottomed plates 

(Corning Glass Works). The culture medium was the same as for 
LC cultures, with either GM-CSF, IL-1, or TNF-a at 10 ng/ml. On 
day 3 of culture (72 hr.s), plates were centrifuged for 5 minutes 
at 300 g and the culture medium replaced with medium containing 
10$ purified allogeneic T-cells without cytokines. These mixed 
epidermal cell-lymphocyte cultures were then incubated for 4 
more days, pulsed with 1 microCurie of 3H-Thymidine (Amersham 
Inc., UK) per well, harvested 16 hr.s later and counts per minute 
(CPM's) assessed with an LBK scintillation counter. 
Blocking Studies 
MELR's were performed as above, however monoclonal 
antibodies to either class I MHC (anti-HLA-A,B,C, produced by the 
hybridoma ATCC # HB95), class II MHC ( ATCC # HB145), or CDIa ( 
ATCC # CRL8020) were added to each set of cultures at the time 
of T-cell addition. T-celi stimulation was measured by ^H- 
thymidine incorporation as above. 
Statistical Analysis of Results 
For LC cultures, experimental and control mean values with 
standard errors were calculated and compared using the Student's 
t-test. For thymocyte cultures all experimental values were 
expressed as percents of control with control values set to 100%. 
Averages and standard errors of experimental values were then 
calculated and compared using a one way analysis of variance 

(ANOVA). In MELR's experimental and control means and standard 
errors were calculated and compared using an ANOVA as above. 
Results 
Langerhans Cell Cultures 
Viability of epidermal cells decreased in a predictable manner 
such that nearly all cells were dead by trypan blue exclusion by 
day 6 (Figure 1). After 2 days of culture, GDI a expression among 
viable cells in medium alone, GM-CSF, IL-1, and TNF-a had 
dropped from 30% upon isolation to 12.4%, 13.5%, 13.0%, and 
11.4% respectively. By day 5 of culture, CDIa expression among 
control cells had dropped to 9.75±/l.2%, while TNF-a and IL-1 
cultured cells were 11.4+.1.2% and 14.5±,Q.4% positive 
respectively. However, only 4.2+0.3% of GM-CSF cultured ceils 
were CDIa positive by day 5 (Figure 2). IL-1 significantly 
prolonged the expression of epidermally associated CDIa antigen 
compared to untreated cultures (p=0.02), while GM-CSF 
significantly decreased CDIa expression (p=0.01). TNF-a did not 
significantly alter CDIa expression in any cultures. 
Thymocyte Cultures 
The percentage of cells expressing CDIa or class I MHC 
antigens after 8 days was determined after culture with the 
indicated cytokines. The number of cells expressing either 

antigen in cytokine treated cultures was divided by the number of 
cells expressing the same antigen in untreated cultures and the 
resulting value multiplied by 100 to give the percent of control 
cells expressing CDIa or class I MHC antigen. Figure 3 shows the 
mean values obtained from 5 such experiments. The percentage of 
cortical thymocytes expressing CDIa on day 8 was 124+12.7% 
(TNF-a), 157±33% (IL-1), and 78+7.4% (GM-CSF) of control, while 
the percentage of cells expressing class I MHC was 109+12%, 
92±8.0%, and 148+34% of the control cultures respectively. Thus 
GM-CSF treatment was associated with accelerated loss of CDIa 
expression from thymocyte cultures (p=0.03), and increased class 
I MHC expression (p=0.02), compared to control. IL-1 was 
associated with effects opposite to those of GM-CSF, maintaining 
the percentage of cells expressing CDIa above control (p=0.01) 
and decreasing the percentage of cells expressing class I MHC, 
however this effect was not significant (p=0.6). TNF-a showed no 
significant effect on either CDIa or class I MHC expression, 
however the small changes it did cause were similar in trend to 
those of IL-1. 
In a well known model of surface antigen expression during 
thymocyte maturation, very early thymocytes are thought to be 
CDIa negative/class I MHC positive, but during differentation 
become CDIa positive/class I MHC negative. These cells again 
become CDIa negative/class I MHC positive as they mature fully 
and exit the thymus [37]. There is also a small, well documented 
population of CDIa negative/class I MHC negative (double 

negative) thymocytes which may represent cells in transition 
between the major populations listed above [37]. In order to more 
clearly define the effects of cytokines on surface antigens at 
various points along this linear differentiation pathway, we 
performed the same experiments with thymocyte populations that 
had been depleted of CDIa and class I MHC positive cells as 
detailed above. 
Figure 4 shows the result of experiments in which CDIa 
positive cells were magnetically depleted from thymocyte 
suspensions prior to culture. In these experiments CDIa 
expression was 108±3.8% (TNF-a), 146±16% (IL-1), and 64±6% 
(GM-CSF) of control, while class I MHC expression was 139+12%, 
220±_17%, and 96^8.8%, respectively. Therefore, GM-CSF 
prevented CDIa expression by CDIa negative/class I MHC positive 
cells (p=0.01). However, GM-CSF had no effect on class I MHC 
expression in this population of thymocytes (p=0.8). This finding 
implies that GM-CSF may either block the maturation of CDIa 
negative/class I MHC positive cells to the CDIa positive/class I 
MHC negative phenotype, or accelerate development of the most 
mature CDIa negative/class I MHG positive thymocytes. In CDIa 
depleted cultures, IL-1 increased the percentage of cells 
expressing CDIa compared to control (p=0.03), an effect opposite 
to that of GM-CSF, and unlike undepleted cultures, IL-1 
significantly increased the expression of class I MHC (p=0.08). 
These effects could be explained if IL-1 was a general 
accelerator of thymocyte maturation moving cells both into and 

out of the CDIa positive/class I MHC negative state. Another 
explanation could be that IL-1 increases the antigen expression 
and/or viability of thymocytes without effecting maturation. In 
this case, the increased percentage of cells expressing these two 
antigens could be explained by larger numbers of viable cells 
expressing antigen, or more cells expressing detectable levels of 
antigen. TNF-a again produced insignificant changes in antigen 
expression in these cultures. 
In a final set of thymocyte experiments, class I MHC positive 
cells were depleted prior to culture yielding thymocyte 
populations that were 80-90% CDIa positive, and containing 
small numbers of CDIa negative/class I MHC negative cells. The 
results of these experiments are shown in figure 5. CDIa 
expression among thymocytes was 126±8.4% (TNF-a), 152+17% 
(IL-1), and 94+3.9% (GM-CSF) of control, while class I MHC 
expression was 122^8.6%, 108^4, and 180±4.0% of control, 
respectively. In these experiments IL-1 significantly increased 
the percentage of ceils expressing CDIa (p=0.03), and GM-CSF 
significantly increased class I MHC expression (p=0.08), while no 
other results were significant. These findings lend additional 
support to the hypothesis that GM-CSF accelerates the maturation 
of CDIa positive/class I MHC negative cells to the CDIa 
negative/class I MHC positive phenotype. In addition these 
results suggest that IL-1 may influence the differentation of 
CDIa negative/class I MHC negative cells to the CDIa 
positive/class I MHC negative phenotype. 
20 
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To summarize the results of these three sets of experiments, 
GM-CSF tended to decrease CDIa expression compared to control 
in undepleted, CDIa depleted, and class I MHC depleted cultures, 
however the effect in this latter set of cultures was small and 
not statistically significant (p=0.6). IL-1 increased CDIa in all 
three sets of cultures, while TNF-a had no effect on CDIa 
expression. GM-CSF increased class i MHC expression compared 
to controls in undepleted and class I MHC depleted cultures, but 
not in CDIa depleted cultures. This is exactly the opposite effect 
and pattern of significance compared to GM-CSF's effect on CDIa. 
IL-1 increased class I MHC expression only in CDIa depleted 
cultures, and as in studies of CDIa, TNF-a had no effect on class I 
MHC expression. This complex pattern of results is summarized 
in table 1. 
In both thymocyte and LC cultures, GM-CSF tended to decrease 
CDIa expression compared to control, while IL-1 increased CDIa 
expression. TNF-a had no effect on CDIa expression in either 
thymocyte or LC cultures. In undepleted thymocyte cultures GM- 
CSF tended to reciprocally effect CDIa and class I MHC, 
decreasing CDIa expresion while enhancing class I MHC 
expression. 
Functional Studies of Langerhans Cells 
As seen in figure 6, LC precultured for 72 hours with GM-CSF 
were more potent stimulators of allogeneic T-cell proliferation 
than cells cultured with IL-1, TNF-a or no cytokine. Specifically, 
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GM-CSF treated LC produced significantly more allogeneic T-cell 
proliferation than LC cultured under all other conditions. This 
was true at all doses of LC tested (p<0.02), except at 300 LC 
where proliferation was the same as control (p=0.5). LC cultured 
with IL-1 showed no significant increase in proliferation at any 
dose tested, while TNF-a treated LC produced less proliferation 
than control, but only at a dose of 900 LC (p=0.05). Figure 7 
shows the results of subsequent experiments concentrating on 
the effect of GM-CSF, and extending the doses of LC used to a 
maximum of 3,000. In these cultures GM-CSF treated LC were 
more potent stimulators of allogeneic T-cells than control cells 
at p<0.01 for all doses of LC tested except at 250 LC where 
p=0.05. Also of note is that there was no significant difference 
in the amount of T-cell proliferation seen in GM-CSF and control 
cultures in which there were no LC even though these wells were 
treated as if they did contain LC during the 72 hour pretreatment 
period. This observation precludes the possibility that it is the 
presence of contaminating GM-CSF that is solely responsible for 
the enhanced T-cell stimulation seen in GM-CSF treated cultures. 
In addition, there was a direct relationship between the number 
of LC in culture and the level of T-cell proliferation, regardless 
of the culture conditions, indicating that GM-CSF augments LC 




Figure 8 shows the results of MELR's in which all Langerhans 
cells were pretreated for 72 hours with GM-CSF. At the time of 
T-cell addition, however, antibodies reactive to either GDI a, 
class I MHC, or class II MHC were added to culture. In these 
cultures the addition of anti-GDI a had no effect on allogeneic T- 
cell stimulation. In cultures treated with anti-class II MHC, 
however, T-cell stimulation was inhibited in cultures containing 
1500 LG or less (p<0.02), while at higher doses of LG, addition of 
anti-class II MHC antibody did not alter levels of T-cell 
stimulation. Most interestingly, when anti-class 1 MHC antibody 
was added to culture there was an inhibition in T-cell 
stimulation at all doses of LG tested (p<0.02). 
Discussion 
The study of LG in vitro has long been hampered by difficulties 
in purifying large numbers of intact cells from the epidermis. By 
modifying the methods used by a variety of different 
investigators, we have developed a technique for rapidly isolating 
human LG without altering their surface phenotype. Many methods 
for LG isolation involve long incubations of skin with the enzyme 
trypsin to obtain epidermal cell suspensions [84], followed by LG 
enrichment by a variety of techniques. These include "panning" 
[77], density gradient centrifugation [76], and fluorescence 
activated cell sorting [85]. While these techniques yield very 
23 

pure populations of LC, they are often long, expensive, and plagued 
by the uncertain effects of trypsin on LC surface proteins. 
Most recently Hanau et a! have described an immunomagnetic 
selection technique where by epidermal cell suspensions are 
stained with a GDI a reactive antibody, and then counterstained 
with a secondary antibody that is conjugated to small iron beads. 
Cell suspensions are then precipitated to a magnetic plate and 
GDI a negative cells washed from the plate. This procedure 
results in a very pure population of LC that can be obtained 
quickly and economically [86]. However, unless the amount of 
magnetic material used is carefully titrated, the resulting LC are 
rendered useless for in vitro functional studies due to the iron 
beads bound to their surface. By incubating skin with the enzyme 
Dispase which is known to digest only fibronectin and type IV 
collagen [87], we have obtained relatively unmodified epidermal 
cell suspensions. These suspensions are then enriched for LC by a 
combination of density gradient centrifugation, and a negative 
immunomagnetic selection that depletes keratinocytes without 
altering LC. This technique is detailed above and routinely yields 
epidermal ceil suspensions 30-50% GDI a positive in 4 to 5 hours. 
Our phenotypic studies of both LC and cortical thymocytes 
suggest that expression of GDI a antigen can be altered by IL-1, 
and GM-CSF. In particular, GM-CSF tended to accelerate the loss 
of GDI a from LC and thymocyte cultures, while IL-1 maintained 
it. The effects of these two cytokines on class I MHC expression 
in thymocyte cultures seemed to be the opposite of their effects 
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on GDI a. That is to say, GM-CSF maintained class I MHC 
expression above control, while IL-1 accelerated its loss from 
nondepleted thymocyte cultures. These results lend credence to 
the notion that GDI a and class ! MHC are reciprocally regulated 
and are consistant with the observation that GDI a and class I MHC 
are reciprocally expressed in vivo [38,39]. Moreover, because 
these cytokines can be produced by keratinocytes [79,82] these 
observations suggest that GM-CSF and IL-1 may play similar roles 
in vivo. While we have shown that the loss of GDI a antigen by 
human LG can be modulated by IL-1 and GM-CSF, for technical 
reasons we were unable to study the effects of these cytokines 
on LG MHG class I expression. As mentioned above however, a 
recent study by Romani et al, has shown that the loss of GDI a 
expression by human LG is accompanied by a rapid increase in 
both class I and class II MHC expression [71]. There remains 
however, no published observations of the effects of epidermally 
associated cytokines on class I MHC expression by LG in vitro. 
Our phenotypic results are consistant with previous work in 
murine systems showing that loss of GDI a analogs can be 
accelerated in vitro by exogenous GM-CSF [69,77]. These studies 
also report that GM-CSF enhances the viability of murine LG in 
vitro. In our study there was no significant difference in 
viability among cells cultured with IL-1, GM-CSF, TNF-a, or 
control as assessed by trypan blue exclusion. This may represent 
an important difference between the behavior of human and 
murine LC in vitro. We are aware of only one study of the effects 
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of cytokines on human LC; Walsh et al have shown that culturing 
GDI a depleted human gingiviai cells with IL-1 induces expression 
of GDI a in these cultures [80], Our data support this finding in 
both human LC and human thymocyte cultures and, as discussed 
below, we have shown that CDIa depleted thymocytes can be 
induced to express CDIa after treatment with IL-1, much as 
gingiviai cells did in Walsh's study. 
In our initial experiments on the effects of GM-CSF, IL-1, and 
TNF-a on CDIa and class 1 MHC expression by unfractionated 
thymocytes, we found that GM-CSF was associated with 
decreased expression of CDIa and increased expression of class I 
MHC, while IL-1 was associated with increased expression of 
CDIa. The significance of these effects during thymocyte 
differentiation are unclear, however, due to the complexity of the 
thymic microenvironment. It is known, however, that thymocyte 
differentiation takes place in a linear fashion with respect to 
surface antigen expression. In particular, it is believed that bone 
marrow derived prothymocytes enter the thymus where they are 
initially CDIa negative/class I MHC positive. During 
differentiation, they become CDIa positive/class I MHC negative, 
and finally as they develop into mature T-cell subsets, they once 
again become CDIa negative/class ! MHC positive [37]. In order to 
isolate subsets of thymocytes at various points along this 
pathway and more precisely determine the effects of cytokines 
during thymocyte development, we performed the CDIa and class I 
MHC depletion experiments detailed above. While the results of 
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these depletion experiments must be interpreted with caution, 
the pattern of effects seen indicates that GM-CSF may prevent 
GDI a expression by ceils of the GDI a negative/class I MHC 
positive phenotype, and enhance expression of class I MHC by 
cells of the GDI a positive/class I MHC negative phenotype. In 
general, this pattern suggests that GM-CSF may be involved in the 
reciprocal regulation of GDI a and class I MHC molecules. When 
explained in the context of the thymocyte differentiation model 
mentioned above, these results imply that GM-CSF may either 
block the development of the GDI a positive/class I MHC negative 
phenotype, and/or accelerate the development of the CDIa 
negative/class I MHC positive phenotype. 
The effects of 11-1 on CDIa and class I MHC expression in 
thymocyte cultures are in general opposite to those of GM-CSF, in 
that IL-1 increases CDIa expression by cells expressing class I 
MHC (CDIa positive/class S MHC negative and CDIa negative/class 
I MHC positive thymocytes), however IL-1 also increases CDIa 
expression by CDIa positive/class I MHC negative thymocytes. 
IL-1 has no effect on class I MHC expression unless CDIa positive 
cells are depleted, in which case IL-1 increases class I MHC 
expression. The observed effects of IL-1 on thymocyte surface 
antigen expression are hard to explain within the context of the 
thymocyte differentiation model discussed above, because IL-1 
tended to increase both CDIa and class I MHC expression by CDIa 
negative/class I MHC positive thymocytes. This effect could be 
accounted for if IL-1 had a significant effect on CDIa 
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negative/class I MHC negative thymocytes in transition between 
the major populations, or if IL-1 enhances the antigen expression 
and/or viability of thymocytes in vitro, in which case more cells 
may appear to be expressing both antigens compared to control. 
We are currently performing experiments using magnetically 
selected GDI a negative/class I MHC negative thymocytes to 
explore the effects of IL-1, as well as GM-CSF and TNF-a on this 
population of ceils. 
Also of note is that TNF-a produced only weak changes in GDI a 
and class I MHC expression which were not statistically 
significant. This is not suprising because while TNF-a production 
has been shown in human thymocytes [92], its effects may have 
been obscured since TNF-a can induce GM-CSF production in a 
variety of cell types [91]. Thymocyte differentiation is 
influenced by a variety of factors including cell-cell contact [93] 
and cytokines released by epithelial and mesenchymal cells [94], 
and while our studies provide only clues to unravelling the 
complex environment of the thymus, they do show that GDI a in 
both skin and thymus is similarly effected by GM-CSF and IL-1 
thus supporting a global role for these cytokines in 
immunoregulation. 
It is becoming increasingly clear from our work and that of 
others that IL-1 and GM-CSF are regulators of immune function 
associated molecules such as MHC class I and GDI a in vitro. 
Since these cytokines are made by normal human keratinocytes in 
vitro [81,82] it is possible that they play some role in the 
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regulation of human LC in vivo. In addition, IL-1 production has 
been demonstrated in thymic epithelial cells [88], and GM-CSF 
production by thymic nonlymphoid cells [89] raising the 
possibility that these cytokines are also involved in the 
regulation of antigen expression by thymocytes in the thymus. 
While evidence of cytokine production by cells of the skin and 
thymus supports the conclusion that the phenotypic regulation we 
have described in vitro may be important in vivo, this evidence 
also presents a problem in the interpretation of our data. For 
example, our LC cultures are typically contaminated with >5 0% 
keratinocytes, and any culture obtained from thymus gland will 
invariably contain contaminating epithelial cells and fibroblasts. 
It is known that IL-1 can induce production of GM-CSF in 
keratinocytes [90], while TNF-a can induce its production in 
fibroblasts, smooth muscle ceils, and endothelial cells [91]. Thus 
the direct effect of exogenous cytokines may be hard to assess 
and it may be that our best attempts to create simple in vitro 
systems still result in a complex interaction of cells and 
signalling molecules, as is the case in vivo. Despite these 
concerns, it seems clear that epidermally associated cytokines 
influence the expression of immune function associated 
molecules on human LC and thymocytes. As discussed below, 
these cytokines also influence the functional abilities of LC in 
vitro. 
It has been known for some time that the ability of human 
Langerhans cells to stimulate allogeneic T-cells increases 
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dramatically after 2-3 days in culture [71,76], and recent murine 
studies have shown that GM-CSF can accelerate the development 
of this ability [69,77]. We have extended this observation using 
human LC. In particular we have shown that human LC precultured 
with GM-CSF for 72 hours are 2-3 times more potent than control 
cells in the stimulation of allogeneic T-cells. While this finding 
may have been predicted from murine studies, it is important in 
light of the differences noted between murine and human immune 
systems. These differences have been demonstrated by the fact 
that human epidermis lacks a cell equivalent to the Thy 1 positive 
dendritic T-cells which represent 2-5% of cells in murine 
epidermis. Since keratinocytes can produce GM-CSF [82], it is 
possible that the exogenous GM-CSF used in these experiments 
merely augmented endogenous GM-CSF in the cultures, thus 
accelerating both the phenotypic and functional changes. Our 
functional studies with TNF-a and IL-1 showed slightly lower 
levels of T-cell proliferation than control, however these results 
were not statistically significant. It is possible that endogenous 
GM-CSF was subtracting from the magnitude of these cytokines' 
effects. We are therefore planning blocking studies using anti- 
GM-CSF antibodies to further isolate the effect of IL-1, TNF-a, 
and endogenous GM-CSF on LC in vitro. It is not clear from our 
studies whether the increased stimulatory capacity of GM-CSF 
cultured cells represents a change in LC physiology or is mediated 
by phenotypic changes such as increased class I MHC or decreased 
CDIa expression. It is clear that the effect is not due to changes 
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in viability of LC in culture since viability was the same in all of 
our experimental and control groups. We were concerned that GM- 
CSF might cause increased allogeneic T-cell stimulation by a 
direct effect on T-cells. This is an unlikely explanation for our 
results for several reasons. For one, LC were carefully washed of 
cytokine containing medium before addition of allogeneic T-ceils. 
Second, wells in which there was culture medium and GM-CSF but 
no LC did not show increased T-cell proliferation compared to 
wells in which there was culture medium, no GM-CSF, and no LC. 
This finding precludes the possiblity that it was the direct effect 
of GM-CSF that was solely responsible for the increase in T-cell 
proliferation seen. It is theoretically possible that a small 
amount of residual GM-CSF stimulated proliferation of allogeneic 
T-cells, but since there was probably some endogenous GM-CSF in 
all cultures, we doubt that it could have had a significant effect. 
Another far less likely possibility is that GM-CSF increases 
the ability of keratinocytes to stimulate allogeneic T-cells. Many 
studies have shown that depleting LC from epidermal ceil 
suspensions renders these suspensions all but devoid of the 
ability to stimulate T-cells [50,95]. Studies comparing the 
ability of injected LC and keratinocytes to prime allogeneic 
reactions in mice show that LC are >10^ times as potent as 
keratinocytes at priming allogeneic reactions to subsequent skin 
allografts [96,97]. It appears then that the ability of 
keratinocytes to stimulate allogeneic reactions is limited at 
best, and it is therefore unlikely that they are capable of inducing 
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the high levels of T-cell proliferation typically associated with 
LC, even under the influence of GM-CSF. 
It is reasonable to say then that the increased stimulation 
seen in our GM-CSF treated cultures is probably due to a direct 
effect on LC. The mechanism of this effect has not been 
discerned in either human or murine systems. It is attractive to 
postulate that this increased functional ability is in some way 
related to the changes in surface phenotype associated with GM- 
CSF pretreatment, and our blocking studies are an attempt to 
explore this possibility. 
In these blocking experiments all LC used were pretreated 
with GM-CSF in order to compare the effects of the three blocking 
monoclonal antibodies used (anti-class I MHC, anti-class II MHC, 
and anti-CDIa) to GM-CSF treated LC alone. As predicted from 
many in vitro and in vivo studies of antigen presentation by LC, 
anti-class II MHC blocked T-cell stimulation in a statistically 
significant way, even though the effect was saturated at higher 
doses of LC. The anti-class II MHC antibody used in these 
cultures was a filtered, titered hybridoma supernatant, and the 
precise concentration of antibody was unknown. It is possible, 
therefore, that high numbers of LC overcame the class IS MHC 
blockade, since the amount of anti-class IS MHC supernatant used 
was constant throughout our cultures. 
An interesting and unpredicted finding from these blocking 
experiments is the significant decrease in T-cell stimulation 
seen in anti-class I MHC treated cultures at all doses of LC 
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tested. This is a novel observation in MELR's using LC, and we are 
unaware of other workers in animal or human systems reporting 
or even attempting this type of blockade. It is possible that the 
anti-class ! MHC antibody added to cultures is producing this 
blockade in an idiosyncratic or nonspecific fashion, however the 
other more interesting possibility is that LC in vitro are involved 
in allogeneic T-cell stimulation in a non-class II MHC restricted 
fashion. There is some indirect evidence to support this notion in 
the findings of Romani et a! which show that human LC 
dramatically increase their expression of MHC class I surface 
antigens after 2 to 4 days in vitro, while increasing their ability 
to stimulate allogeneic reactions [71]. 
Finally, the addition of anti-CDIa monclonal antibody had no 
effect on the levels of T-ceii stimulation seen when comapared 
to control cultures without blocking antibodies. CD1 a has many 
similarities to MHC class I molecules as discussed above [26-35], 
and it has been speculated that CDIa may then have a function 
similar to class I MHC molecules, namely antigen presentation to 
CD8 positive T-cells [57,97]. CD8+ T-cells are generally 
associated with suppressor and cytotoxic functions [54], and 
their proliferative response to stimulation is generally smaller 
and shorter in duration than that of CD4+ cells [99]. CD8+ cells 
are also difficult to grow because they often kill the cells that 
stimulate them [100], and have stringent growth requirements 
including the presence of IL-2 [101]. As a result, stimulation of 
CD8+ cells by LC bearing CDIa could easily be overlooked in 
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MELR's containing large numbers of CD4+ cells. If such 
stimulation were obscured, blockade of stimulation would surely 
be obscured as well. Thus, the lack of blockade of T-cell 
stimulation by anti-CDI a antibody in our cultures does not 
preclude the possibility that GDI a is functioning as an antigen 
presenting molecule for a subset of CD8+ lymphocytes. 
In order to explore the possibility of class I MHC ( or GDI a) 
stimulation of CD8+ cells in vitro, we are planning a series of 
experiments using GM-CSF cultured LG and fractionated CD4+ and 
CD8+ subsets of T-ce!ls in MELR’s. In addition, these experiments 
will use IL-2 in T-cell culture medium in order to amplify the 
proliferative response of CD8+ cells [101]. These experiments 
may shed additional light on the possibility of LG stimulating 
allogeneic T-cel!s in a non-class II MHC restricted fashion. Early 
results from these experiments indicate that LG can induce 
proliferation in allogeneic CD8+ T-cells. This finding is a very 
important piece of evidence in proving that LG stimulate the 
immune system through circuits other than the MHC class II/CD4+ 
T-cell pathway. However, more work is required to confirm this 
very preliminary finding. There is some evidence that LG present 
antigen in a non-MHC class II restricted fashion in a recent study 
by Porcelli et al. In this study, the authors demonstrate the 
specific recognition of GDI a by a CD4‘/GD8‘ (double negative) 
cytotoxic T-cell line which causes direct lysis of GDI a bearing 
cells [102]. Furhtermore, this lysis can be blocked with anti- 
GDI a monoclonal antibodies [102]. The GDI a positive cells used 
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in this study, however, were the MOLT-4 thymic leukemia cell 
line and thus proof of non-MHC class II restricted antigen 
presentation by physiologic LC is still lacking. While a great deal 
of work is still needed to understand the regulation of LC and 
their unique surface antigen CDIa, work like ours and Porcelli's 
has begun to describe the regulation of the observed phenotype 
and function of LC, and may eventually lead to a precise 
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Figure 1. viability of Langerhans cells in vitro as assessed on days 
0, 2, 3, 5, and 6 of culture by trypan blue exclusion. There was no 
difference in viability in cultures treated with IL-1, GM-CSF, TNF-a, 
or control. 

Figure 2. percentage of cells expressing CDIa surface antigen as 
assessed by flow cytometry on days 0, 2, 3, and 5 of culture. By day 
5 control cells were 9.75±1.2% CDIa positive, while GM-CSF treated 
cells expressed significantly lower levels of CDIa (4.2^0.26%, 
p=0.01), and IL-1 treated cells expressed significantly more CDIa 
(14.45±0.04%, p=0.02). TNF-a did not produce a significant change in 
CDIa expression (11.35+1.2%, p=0.5). 

250 
Figure 3. Undepleted thymocyte cultures. GM-CSF was associated 
with decreased GDI a expression (78+7.4%, p=0.03), and increased 
MHC I expression (148±34%, p=0.02). IL-1 was associated with 
increased GDI a expression (157^33%, p=Q.Q1), while all other 
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Figure 4. MHC I depleted thymocyte cultures. GM-CSF was 
associated with increased MHC I expression (180+4.0%, p=0.008), and 
IL-1 with increased CDIa expression (152±17%, p=0.03). All other 
effects were insignificant. 

250 
Figure 5. CDIa depleted thymocyte cultures. GM-CSF was 
associated with decreased CDIa expression (64±6%, p=0.01), IL-1 
was associated with increased CDIa expression (146+16%, p=0.03), 
and increased MHC I expression (22G±17%, p=0.08). AH other effects 
were insignificant. 

Figure 6. Langerhans cell/T-cell MELR. LC pretreated with IL-1 
produced levels of T-cell proliferation unchanged from control, as 
did LC pretreated with TNF-a (except at 900 LC where TNF-a 
produced significantly less T-cell proliferation than control p=0.05). 
GM-CSF pretreatment produced significantly increased levels of T- 

















Figure 7. Langerhans cell/T-cell MELR focusing on GM-CSF. GM-CSF 
produced increased levels of T-cell proliferation at p<0.01 at all 
doses of LC tested except 250 where p=0.Q5. In wells in which there 
were no LC there was no difference in the amount of T-cell 
proliferation seen in control versus GM-CSF treated cultures (p=0.3). 

Figure 8. Langerhans cell/T-cell MELR in which all LC were 
pretreated with GM-CSF. At the time of T-cell addition, blocking 
antibodies to either MHC I, MHC II, or CDIa were added to culture. 
Anti-MHC II produced a significant reduction in T-cell proliferation 
at 0-1500 LC (p<0.03), but no reduction at 2000-3000 LC (p=0.5). 
Anti-MHC I produced a significant reduction at all doses of LC 
(p<0.03). Anti-CDIa did not produce a significant change in T-cell 
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